---
title: "STOCKS | Akeso Approves Up to HK$200 Million Share Buyback in Open Market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289413084.md"
description: "Akeso (9926) said its board has approved using up to HK$200 million to purchase the company’s shares in the open market. According to Ming Pao, the purchases will be carried out by the trustee of the company’s 2021 Restricted Share Unit Scheme and funded from existing available cash resources."
datetime: "2026-06-11T04:49:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289413084.md)
  - [en](https://longbridge.com/en/news/289413084.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289413084.md)
---

# STOCKS | Akeso Approves Up to HK$200 Million Share Buyback in Open Market

Akeso (9926) said its board has approved using up to HK$200 million to purchase the company’s shares in the open market. According to Ming Pao, the purchases will be carried out by the trustee of the company’s 2021 Restricted Share Unit Scheme and funded from existing available cash resources.

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Akeso Launches HK$200 Million Share Purchase as Leadership Boosts Stakes](https://longbridge.com/en/news/289413457.md)
- [UBS Reaffirms Their Buy Rating on Akeso, Inc. (9926)](https://longbridge.com/en/news/289649001.md)
- [China’s NMPA approves Akeso’s gumokimab for plaque psoriasis](https://longbridge.com/en/news/289582499.md)
- [21:57 ETAkeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio](https://longbridge.com/en/news/289535144.md)
- [SSY Group Boosts Employee Incentive Pool with Open-Market Share Purchase](https://longbridge.com/en/news/289578325.md)